Literature DB >> 21242344

Epidermodysplasia verruciformis in human immunodeficiency virus-infected patients: a marker of human papillomavirus-related disorders not affected by antiretroviral therapy.

Simon Jacobelli1, Helene Laude, Agnes Carlotti, Flore Rozenberg, Jean Deleuze, Jean-Pierre Morini, Nathalie Franck, Isabelle Gorin, Marie-Francoise Avril, Nicolas Dupin.   

Abstract

BACKGROUND: Skin eruptions resembling epidermodysplasia verruciformis (EV) are rarely observed in immunocompromised patients. We focused on the epidemiologic, clinical, virologic, and immunologic features of EV in human immunodeficiency virus (HIV)-positive patients. OBSERVATIONS: We studied 11 HIV-positive patients (6 men and 5 women) with clinical and histological features of EV observed at our department. The median age at HIV diagnosis was 27 years. At the onset of eruption, the median age was 40 years and the median CD4 T-cell count was 170/μL. Clinical presentation included flat warts (n = 11), pityriasis versicolor-like macules (n = 5), and lichenoid papules (n = 3) on sun-exposed skin. Detection and typing of cutaneous human papillomavirus (HPV) were carried out in 8 cases and always revealed β-HPV infection, including oncogenic HPV-5 or 8 (n = 6). Mucosal HPV-related diseases were present in 7 cases. Histories of skin cancer and lymphoproliferative disorder were recorded in 3 and 4 patients, respectively, including 2 fatal cases. Skin eruption was never improved by highly active antiretroviral therapy (HAART). In 2 cases, EV was associated with an immune reconstitution syndrome. The present series is the largest with a complete characterization. A review of similar cases was carried out.
CONCLUSION: Despite effective HAART, HIV-infected patients with EV require a prolonged and careful follow-up to detect mucosal HPV-related diseases, lymphoproliferative disorders, and skin cancers.

Entities:  

Mesh:

Year:  2011        PMID: 21242344     DOI: 10.1001/archdermatol.2010.399

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  8 in total

Review 1.  HIV-Related Skin Disease in the Era of Antiretroviral Therapy: Recognition and Management.

Authors:  Khatiya Chelidze; Cristina Thomas; Aileen Yenting Chang; Esther Ellen Freeman
Journal:  Am J Clin Dermatol       Date:  2019-06       Impact factor: 7.403

Review 2.  Epidermodysplasia verruciformis in an HIV-infected man: a case report and review of the literature.

Authors:  Amit Kaushal; Shane Silver; Ken Kasper; Alberto Severini; Sate Hamza; Yoav Keynan
Journal:  Top Antivir Med       Date:  2012-12

3.  Cutaneous manifestations of human immunodeficiency virus: a clinical update.

Authors:  Kirstin Altman; Erin Vanness; Ryan P Westergaard
Journal:  Curr Infect Dis Rep       Date:  2015-03       Impact factor: 3.725

4.  Cutaneous squamous cell carcinoma in vertically acquired HIV and epidermodysplasia verruciformis.

Authors:  Linda A Mandikiyana Chirimuta; Francis J Ndowa; Margaret J Pascoe
Journal:  South Afr J HIV Med       Date:  2022-06-27       Impact factor: 1.835

5.  Acquired epidermodysplasia verruciformis due to multiple and unusual HPV infection among vertically-infected, HIV-positive adolescents in Zimbabwe.

Authors:  S M Lowe; L Katsidzira; R Meys; J C Sterling; M de Koning; W Quint; K Nathoo; S Munyati; C E Ndhlovu; J R Salisbury; C B Bunker; E L Corbett; R F Miller; R A Ferrand
Journal:  Clin Infect Dis       Date:  2012-04-03       Impact factor: 9.079

6.  Epidermodysplasia Verruciformis-like Skin Eruption in an HIV-positive Patient.

Authors:  Juliana C Boza; Juliano Peruzzo; Fabiana Bazanella de Oliveira; Fernanda Luca Nazar; Renato Marchiori Bakos
Journal:  Trop Med Health       Date:  2014-08-23

7.  Cutaneous Manifestations of Human Immunodeficiency Virus/AIDS Patients in Albania.

Authors:  Erjona Shehu; Arjan Harxhi; Artan Simaku
Journal:  Int J Appl Basic Med Res       Date:  2019-10-11

8.  The transmembrane channel-like protein family and human papillomaviruses: Insights into epidermodysplasia verruciformis and progression to squamous cell carcinoma.

Authors:  Jaime S Horton; Alexander J Stokes
Journal:  Oncoimmunology       Date:  2014-04-15       Impact factor: 8.110

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.